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Background: The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-
related osteonecrosis of the jaw (BRONJ). 
Material and Methods: Case-control studies comparing the different concentrations of a series of molecules de-
tected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA 
guidelines for systematic reviews were used for the present paper. Two reviewers independently screened elec-
tronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of 
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Introduction
Bisphosphonates (BPs) are analogues of pyrophosphate 
which have potent inhibitory effects on bone resorption 
(1,2). These bone targeted-therapies are widely used for 
osteoporosis and different types of cancers. BPs have 
been proven to reduce the risk of skeletal-related events 
(SREs), delay the onset of SREs and ease bone-related 
pain (3).
There are two main classes of BPs from a chemical 
standpoint: non-nitrogen containing bisphosphonates 
(i.e. etidronate and clodronate) and nitrogen containing 
bisphosphonates (nBPs); this last group is subdivided 
into the alkyl-amino bisphosphonates (i.e. pamidronate, 
alendronate and ibandronate) and the heterocyclic nitro-
gen containing bisphosphonates (i.e. risendronate and 
zolendronate) (4,5).  
Non-nitrogen containing bisphosphonates are metabo-
lised in the cells to an adenosine triphosphate derivative 
that impairs osteoclast function and induces osteoclas-
tic apoptosis. In the case of nBPs, the bone-targeting 
pharmacokinetic properties of these drugs cause se-
lective inhibition of farnesyl diphosphatase synthase 
and a reduction in the production of prenylated forms 
of guanosine thiphosphate biding proteins (GTPases) 
causing an inhibition of osteoclast activity and gener-
ating an increase in bone turnover and bone mineral 
density (BMD) (6). nBPs have a higher relative potency 
in relation to non-nitrogen containing bisphosphonates. 
Alkyl-amino bisphosphonates are 100 ~1000 times 
more potent that non-nitrogen containing bisphospho-
nates. Third-generation BPs also known as heterocyclic 
nitrogen containing bisphosphonates have the highest 
relative potency of all BPs, they are 1000 ~20000 times 
more potent that etidronate (1,4).  
Bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) is infrequent sequelae of these types of anti-
resorptive drugs (7). According to the American Asso-
ciation of Oral and Maxillofacial Surgeons (AAOMS), 
BRONJ is defined as an area of exposed bone in the 
maxillofacial region in a patient treated with bisphos-
phonates (BPs) and who did not receive radiotherapy in 
the craniofacial region that does not heal during the 8 
weeks following its identification by a health care pro-
vider (8). The physiopathology of this outcome remains 
Results: From a total of 601 identified studies, 7 (4 articles with high methodological quality and 3 with medium) ar-
ticles were included. They investigate 2623 patients, of whom 91 (3.47%) developed BRONJ. A total of 7 biomarkers 
were identified and classified into 3 groups: bone turnover, angiogenesis and endocrine markers. Conflicting results 
were found in relation to most biomarkers.
Conclusions: The present review suggests that no useful markers are currently available to evaluate BRONJ risk. 
Nevertheless, the present paper indicates that a paradigm shift from bone turnover biomarkers to angiogenesis and 
endocrine markers could shed light on this search.  
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partially unknown; however, currently there are three 
main theories to explain its aetiology: 1) inhibition of 
osteoclast activity with a suppression of bone turnover, 
2) the relationship of inflammation with infection, and 
3) inhibition of angiogenesis (9,10). These explanations 
arise from the current state-of-the-art in bone biology. 
The maxillary and mandible bones concentrate a 
greater proportion of BPs than other bone tissues due 
to their relatively higher bone turnover ratio (11). This 
remodelling rates cause an alveolar bone cortical thick-
ness (12). In addition, to this osteoclastic activity sup-
pression, BPs can also suppress angiogenesis through 
an inhibitory effect on vascular endothelial cells (13). 
Furthermore, the presence of microflora distinct to the 
oral cavity has been recently considered as a potential 
trigger or stimulating factor in the progress of this out-
come; in this sense, BRONJ-related bone sequestra have 
shown the presence of bacteria such as Fusobacterium, 
Eikenella, Bacillus, Actinomyces, Staphylococcus and 
Streptococcus (14). This biofilm causes an increase of 
circulating cytokines and a dysfunction of matrix pro-
teases which leads to a chronic inflammatory response 
(13). Impaired macrophage function following bacterial 
stimulation may be linked to this outcome. Since os-
teoclasts and macrophages have the same cell lineage 
(i.e. granulocyte/monocyte progenitor); it’s plausible 
that BPs inhibit the activity of macrophages and also 
the differentiation from macrophage/monocyte to os-
teoclasts (15).
On the other hand, at the systemic and oral levels, there 
are fundamental risk factors involving the aetiology of 
the entity that must be understood. At the oral level, the 
risk factors include dental extraction and periodontal 
disease. At a systemic level, different types of treat-
ments, such as chemotherapy, treatment with cortico-
steroids and anti-angiogenic therapies, are risk factors 
associated with BRONJ. Other factors related to the 
development of BRONJ are closely related to BPs, such 
as the type of medication, route of administration and 
duration of treatment (10). In addition, certain genetic 
predispositions have also been described, including 
CYP2C8 gene polymorphisms, vascular endothelial 
growth factor gene polymorphisms, and mutations in 
the prothrombin gene (16). Recently, other drugs have 
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been linked to osteonecrosis of the jaw onset, such as 
inhibitors of nuclear factor-kB ligand (RANKL), an-
giogenesis inhibitors, tyrosine kinase receptors  and 
tumour necrosis factor alpha (TNF-α) have been identi-
fied, motivating the name change to ‘medication-related 
osteonecrosis of the jaws’ (MRONJ) (17).
In 2003, Marx described the first case series of BRONJ-
affected patients (18). In 2007, this same author pro-
posed carboxy-terminal collagen crosslinks in serum 
(sCTX) as a biomarker to predict the risk of recurrence 
of this unwanted complication in a patient undergo-
ing antiresorptive treatment. The data suggested that a 
CTX value below 100 pg/ml represents a high risk of 
BRONJ relapse, values between 100 and 150 pg/ml rep-
resent a moderate risk, and values greater than 150 pg/
ml represent a minimal risk (19). This biomarker was 
later proved not to be predictive. In fact, a recent meta-
analysis confirms its inefficiency in this regard (20). 
The main reason for the dysfunction of this biomarker 
according to the American Society for Bone and Min-
eral Research (ASBMR) task force is that low sCTX 
levels are simply a reflection of the pharmacological 
effects of antiresorptive therapies (21). The positioning 
of the AAOMS in 2014 confirms that non-predictive 
biomarkers are available for this pathological entity 
(8). Since then, different researchers worldwide have 
focused their efforts on identifying useful markers for 
this pathology. 
As observed, there is a lack of consensus in the litera-
ture regarding the use of biomarkers to predict the on-
set of BRONJ; both the AAOMS (8) and the ASBMR 
(7) agree on that there is insufficient evidence to prove 
the efficacy of any biomarker in the BRONJ prevention 
protocols. To our best knowledge no previous system-
atic approach to this emerging topic can be found in the 
literature.
In the present review, the most relevant advances 
achieved to date in the search for a biomarker to as-
sess the risk of developing BRONJ are comprehensively 
compiled and discussed. We will focus on serum and 
urine markers, describing only briefly some investiga-
tions on alternative matrices. We will only review re-
search that seeks to establish the risk of disease prior to 
development of said disease, not biomarkers that evalu-
ate prognosis or staging.  
Material and Methods
-Search protocol
The protocol of this systematic review was designed by 
AL-P and registered in PROSPERO (CRD42017078149). 
This review was conducted based on the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and 
Meta-analysis) guidelines (22). 
The review used the PICO methodology: adults (P = pa-
tients); development of BRONJ; (I = intervention), no 
development of BRONJ (C = comparison); correlation 
with a biomarker (O = outcome. The objective was to 
answer the following question: What are the most effec-
tive biomarkers for the risk assessment of developing 
BRONJ?
-Eligibility criteria
To select the studies included in this systematic review, 
the publications had to meet the following criteria: 1) 
prospective or retrospective case-control studies; 2) 
performed on humans older than 18 years; 3) research 
evaluates biomarkers to predict the presence of mandib-
ular osteonecrosis in patients treated with bisphospho-
nates; 4) data on the type of BP, duration of treatment 
and route of administration must be provided; and 5) the 
diagnostic criteria of BRONJ must be valid (7,8).
Criteria for exclusion were as follows: 1) contained less 
than 10 patients; 2) included patients under 18 who con-
sumed BPs due to osteogenesis imperfecta; 3) written 
in a language other than English; 4) publications with 
redundant material; 5) animal studies; 6) included pa-
tients treated with radiotherapy in the maxillofacial re-
gion; and 7) dealt with other entities similar to BRONJ 
(e.g., oral ulceration and bone sequestration (OUBS)) or 
whose origin is attributed to other drugs. 
-Systematic search
A review was made using the MEDLINE databases (via 
PubMed, from September 2003 to September 2017), 
Web of Science (WOS) (from September 2003 to Sep-
tember 2017) and The Cochrane Library (CL) (from 
September 2003 to September 2017). This search was 
performed during October 2017.  A manual search was 
also performed in a series of journals: Bone; British 
Journal of Oral and Maxillofacial Surgery; Internation-
al Journal of Oral and Maxillofacial Surgery; Journal 
of Oral Maxillofacial Surgery; Journal of Cranio-Max-
illofacial Surgery; Oral Surgery, Oral Medicine Oral 
Pathology and Oral Radiology and Oral Oncology. Po-
tentially relevant articles that were known to any of the 
review authors and reference lists of retrieved articles 
were also checked.
The search in PubMed via Medline was based on the 
following terms: ((diphosphonates OR bisphosphonates 
OR antiresorptive) AND (osteonecrosis OR jaw osteo-
necrosis) AND (biomarkers OR biological markers)). 
The search used both MeSH terms and free search. This 
search was conveniently adapted for use in WOS and 
CL. 
-Data extraction and analysis 
Data extraction and collection were performed by a 
group of research experts in the field of oral surgery 
(AL-P and MP-S) and a maxillofacial surgeon (AG-G) 
according to the previously described criteria. All ab-
stracts and research titles that emerged from the initial 
search were analysed. Once that first screening was per-
formed, the full texts of selected papers were analysed. 
Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24 (1):e26-36.                                                                                                                  Biomarkers for biphosphonate-related osteonecrosis of the jaw
e29
The reason for exclusion was recorded for those items 
that were eliminated in this phase. Consensus between 
the main researchers (AL-P and MP-S) was acceptable 
during the inclusion process. The agreement in this pro-
cess was calculated using Cohen’s kappa coefficient, 
and a κ score of 0.8 was obtained. In case of discrep-
ancy, the third researcher (AG-G) acted as a mediator. 
The following data were extracted and analysed in all 
the studies included in the review: sample size, criteria 
for the diagnosis of BRONJ, type of BP, route of ad-
ministration, underlying disease, covariate adjustment, 
biomarker (matrix) and main results.
-Risk of bias evaluation
The methodological quality of the included studies and 
the possibility of bias were assessed using the New-
castle-Ottawa Scale (NOS) (23). This scale measures 
three dimensions (selection, comparability of cohorts, 
and outcome) with a total of 9 items. In the analysis, 
the studies with NOS scores of 1-3, 4-6 and 7-9 were 
defined as low, medium and high quality, respectively. 
This analysis was executed for each study independent-
ly by AL-P and MP-S. In the case of a disagreement 
between the two researchers, a third researcher (AG-G) 
acted as mediator. 
Simultaneously, an individual assessment of each item 
was obtained regarding the level of evidence (LoE) ac-
cording to the Oxford CEBM Levels of Evidence clas-
sification (24).
Results
The search process was reduced to 601 titles and ab-
stracts that were subjected to evaluation after elimi-
nating 48 duplicate publications. After reading the ab-
stracts, 535 articles were eliminated because they did 
not meet the criteria. After examining the full text, 11 
documents were excluded for different reasons. There-
fore, 7 articles were included in the present systematic 
review (Fig. 1). 
A summary of the 7 selected articles (25-31) and their 
main results can be found in Table 1, 1 continue. The 
studies are organized chronologically from the oldest to 
the most recent publication. 
These works were performed in 6 different countries 
on four continents (Europe, Asia, America and Ocea-
Fig. 1. Flow diagram of the systematic review.
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nia). All studies were published between 2009 and 2017. 
The sample sizes of the included works varied from 
50 subjects in the study by Topaglu et al. (31) to 1900 
subjects in the study by Hutchenson et al. (30). In to-
tal, the review includes 2623 patients, of whom only 91 
(3.47%) developed BRONJ. In relation to the diagnosis 
of BRONJ, the most widely used criteria were those 
of AAOMS (8), used in 4/7 of the studies (Table 1, 1 
continue). The global distribution regarding the types 
of BPs used by the patients was as follows: 812 alen-
dronate (57.02%), 8 clodronate (0.56%), 2 etidronate 
(0.14%), 16 ibandronate (1.12%), 7 pamidronate (0.49%), 
469 risedronate (32.77%), 100 zoledronate (6.99%) and 
13 other combinations (0.91%). The following underly-
ing diseases were noted in the patients: 1361 osteoporo-
sis (91.77%), 40 breast cancer (2.70%), 31 multiple my-
eloma (2.09%), 19 bone metastases (1.28%), 11 prostate 
cancer (0.74%), 8 lung cancer (0.54%), 5 Paget’s disease 
(0.34%), 3 kidney cancer (0.20%), 2 nasopharyngeal 
cancer (0.13%), 2 thyroid cancer (0.13) and 1 neurogenic 
cancer (0.07%). Three included articles (25,28,29) did 
not specify the primary malignant diseases responsible 
for bone metastases.
A total of 7 biomarkers were identified and classified 
into three groups: bone turnover biomarkers (i.e., bone 
alkaline phosphatase (BAP), c-terminal telopeptide 
cross-link of type I collagen (CTX), deoxypyridinoline 
(DPD), N-telopeptides of bone type I collagen (NTX), 
osteocalcin (OC)), endocrine biomarkers (i.e., parathy-
roid hormone (PTH)), and angiogenesis markers (i.e., 
vascular endothelial growth factor (VEGF)). 
The marker most frequently used was CTX, used in 6 
of the 7 investigations; this marker was only reported 
as a predictor of BRONJ in two studies (26,30). VEGF 
was also shown to be predictive in a single study (27). 
PTH was predictive in one study of the two studies that 
evaluated it (28). On the other hand, BAP, DPD, NTX 
and OC were not effective predictors in any study (Ta-
ble 1) (26,28).
Regarding the evaluation of the risk of bias according to 
NOS (23), 4 articles with high methodological quality 
were identified with NOS scores between 7-9 (25,28), 
and 3 articles were of medium quality with scores be-
tween 4-6 (29-31) (Fig. 2). The level of evidence of all 
the works included according to the aforementioned 
classification was IIIb (24).
 
Fig. 2. Risk of bias assessment according to NOS (16).
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Discussion
The search for useful predictive markers to assess 
the risk of BRONJ onset has proved to be extremely 
complex due to its low incidence, estimated at 0.7 per 
100,000 people per year (8). Evidence of this low in-
cidence is the small number of documents included in 
this review. On the other hand, numerous papers evalu-
ate these biomarkers after the pathology has already oc-
curred in an attempt to assess the risk of a relapse after a 
¨drug holiday¨ or to identify markers that correlate with 
disease stage (32-35). Not all drug holidays are useful 
in preventing this pathology because based on their 
pharmacokinetic nature, BPs irreversibly accumulate 
in the bone in a very short period of time (8). The total 
prevalence of BRONJ in the present review was 3.47% 
of the total number of patients. This value is within the 
range of previous epidemiological studies in similar 
communities, 0.01-12%. It’s important to highlight that 
prevalence range from under 1% for patients with pri-
mary osteoporosis and up to about 20% for high-risk 
subpopulations (i.e. patients with a malignant disease 
and further local or systemic risk factors) (17). 
The BPs most frequently used by the patients in this re-
view were alendronate and risedronate (98.79%), which 
are considered first choice antiresorptive drugs in os-
teoporotic patients. The third most used BP was zole-
dronate (6.99%), which is a good option for osteoporo-
sis in cases of digestive intolerance, poor adherence to 
treatment or increased risk of bone fractures. For many 
oncologic diseases (i.e. breast cancer, multiple myeloma 
or prostate cancer) zoledronate has proven to be the 
drug of first choice. In case of renal failure, patients are 
more likely to experience renal impairment with zole-
dronate, which is why in these situations it is advisable 
to use ibandronate (36). 
It should be noted that Marx et al. suggested the use 
of CTX as a biomarker of the risk of relapse (19). To 
the best of our knowledge, the first work to assess the 
utility of CTX as a biomarker of initial risk was car-
ried out by Kunchur et al. (25). This distinction in the 
search for markers to predict this pathology has not 
been addressed to date. However, recently, McGowan 
et al. postulated a list of potential serum biomarkers 
(i.e., VEGF, ESR, CRP and CTX) (37). We classified 
the list of markers produced in this systematic review 
into three groups: bone turnover biomarkers, endocrine 
biomarkers and angiogenesis markers. These markers 
were nominated by the current BRONJ aetiopathogenic 
model at the time and given their intimate relationship 
with osteoporosis (6).
In the case of osteoporosis, bone turnover biomarkers 
present a series of individual limitations that prevent os-
teoporosis from being useful for diagnosis (6,38). In fact, 
its basic utility in medicine is to advise the response to 
treatment. Some inherent limitations of these biomark-
ers are highlighted below. BAP has a low sensitivity and 
specificity in the study of bone metabolic disease and is 
not useful in patients with hepatic disorders. Osteocal-
cin appears altered in states of liver failure. CTX and 
NTX do not exclusively measure bone metabolism but 
all the tissues that contain type I collagen. Finally, DPD 
is currently considered a non-discriminatory marker in 
bone pathology. In the study of osteoporosis, the current 
gold standard biomarker is CTX, which has a good cor-
relation with BMD. It’s important to consider that bone 
turnover biomarkers fall within wide limits. This factor 
jeopardizes the validity of strategic planning through 
biomarker sampling in relation to this outcome (39).
Specifically, regarding BRONJ, this score is not useful 
according to the results of this review despite the sig-
nificant heterogeneity of the data. The recent system-
atic reviews of Dal Prá et al. (40) and Enciso et al. (20) 
reached the same conclusion. An important limitation is 
the significant divergence between the control groups, 
among which healthy subjects (29,30), patients treated 
with BPs (27) or patients who consume BPs undergo-
ing dentoalveolar surgery are included (25,26,28,31). In 
total, 91.7% of the patients included in this review suf-
fered from osteoporosis as an underlying disease. This 
finding is consistent with a recent review in which it 
was also the most frequent pathology (40). The lack of 
correlation between these biomarkers and the develop-
ment of BRONJ indicates that the correct therapeutic 
control of the underlying disease does not seem to play a 
key role in the prevention of BRONJ. Studies that evalu-
ated these biomarkers in patients who stopped consum-
ing BPs and in controls who continued with these treat-
ments also did not find these biomarkers useful (35). 
Kim et al. (28) performed an analysis of ROC curves 
for some of these biomarkers, in which CTX reached a 
sensitivity of 29.73% and a specificity of 89.19% with 
a cut-off value of ≤ 0.094 ng/ml. However, Hutcheson 
concluded that a CTX value <150 pg/ml at the time of 
tooth extraction is associated with a 3-fold increased 
risk of developing BRONJ (30). In our opinion, the use 
of these markers is not justified for assessing the risk 
for developing BRONJ, and scientific evidence is not 
available to support their use in a therapeutic protocol. 
However, caution should be taken when assessing this 
statement due to the limited number of BRONJ cases 
or the within-group heterogeneity in the control groups. 
It has been postulated that the inhibition of angiogen-
esis can play a key role in the development of BRONJ 
(9,41). This relationship is due to the role that osteo-
clasts play in angiogenesis. Osteoclasts are actively in-
volved in the production of blood vessels through the 
production of matrix metalloproteinase-9 (MMP-9). 
Zoledronate and pamidronate inhibit the production 
of MMP-9 and subsequently angiogenesis (42). Taking 
into account the higher concentration of BPs that occurs 
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in the maxillary bones, it seems reasonable that this ef-
fect plays a key role in the development of this pathol-
ogy (43). The biomarker that was proposed in this study 
was VEGF. VEGF is a fundamental protein in vasculo-
genesis and angiogenesis and therefore considered an 
important biomarker in some autoimmune pathologies 
and tumours. Its outstanding role in relation to BRONJ 
is demonstrated by the described cases of osteonecrosis 
of the jaw induced by bevacizumab, a monoclonal anti-
body that acting on VEGF inhibits angiogenesis (17). In 
the only series of patients in this review in which VEGF 
was used as a biomarker, it was found to be predictive 
(27). Later, Thumbigere-Math et al. demonstrated that 
it was useful as a biomarker in patients who suffered 
BRONJ after a long discontinuation of the treatment 
(35). The evidence regarding this biomarker is limited, 
and the development of new research is needed to assess 
its inclusion in the risk protocols. Despite this notion, 
VEGF seems to have a promising future. A recent study 
of salivary proteomics in patients with BRONJ also 
demonstrated significantly increased levels of MMP-9 
with respect to patients treated with BPs who did not de-
velop this pathology (44). A body of evidence has estab-
lished that expression or activity of metalloproteinases 
(MMPs) may be stimulated by periodontal diseases; 
these mechanisms could in part explain the high comor-
bidity of periodontal disease and BRONJ (45). 
The last group of biomarkers treated in this review is 
the endocrine biomarkers. The possible relationship be-
tween the appearance of BRONJ after a period of hy-
pocalcaemia and secondary hyperparathyroidism has 
been proposed (46). Evidence suggests that PTH plays 
a key role in angiogenesis given that treatment with 
parathyroid hormone related protein (PTHrP) in vivo in-
creases the number of blood vessels and the number of 
osteoclasts (42). Recently, a novel treatment for BRONJ 
has been reported based on the use of teriparatide, an 
analogue of human parathyroid hormone, whose future 
looks promising in the treatment of BRONJ despite the 
limited existing evidence (17). The results of the pres-
ent review are conflicting in this sense. On one hand, 
the series by Kim et al. highlights PTH as a useful bio-
marker in an analysis using ROC curves with a cut-off 
value of >41.52 pg/ml, a sensitivity of 56.52% and a 
specificity of 86.67% (28). In contrast, in the series by 
Lazarovici et al., this biomarker was not predictive (26). 
More research is needed to determine whether this bio-
marker is useful. Other biomarkers related to the endo-
crine system, such as triiodothyronine (T3) and thyroid 
stimulating hormone (TSH), have been used to evaluate 
the risk BRONJ relapse after a long discontinuation of 
BP consumption; however, these biomarkers were not 
effective (35). 
Some investigations have suggested the use of other 
biomarkers that have not yet been used predictively, 
including C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), interleukin-17 (IL-17), α-CTX, 
tartrate-resistant acid phosphatase 5b (TRACP 5b), re-
ceptor activator for nuclear factor κ B ligand (RANKL), 
and osteoprotegerin (OPG) (21,28,34,35). The most 
commonly used matrices in search of these biomarkers 
are serum and urine. Recently, saliva has also been used 
in the search for biomarkers (44,47-49). In this regard, 
a series of proteins whose levels are altered in BRONJ 
patients’ saliva have been detected; mainly molecules 
in relation to oxidative stress (i.e. glutathione, malondi-
aldehyde, oxidized glutathione, and 8-oxo-7,8-dihydro-
2-deoxyguanosine) (47), interleukins (i.e. Interleukin-1 
alpha, interleukin-1 receptor antagonist, interleukin 1 
beta, and interleukin-6) (48,49) and other proteins (des-
moplakin, metalloproteinase-9, mammaglobin-B, car-
bonic anhydrase II, etc) (44).
The present systematic review has certain limitations. 
The results are affected by the great variety of health 
and disease states of the participating subjects, the va-
riety of drugs, administration routes, treatment times, 
different covariate adjustment, and the different defi-
nitions of BRONJ applied. It should be noted that the 
search for an adequate protocol to predict the risk of 
suffering from BRONJ or simply provide information 
regarding its management, regardless of the search for 
markers, appears to still be in the distant future. 
Although the current evidence regarding the use of 
biomarkers to assess the risk of suffering from BRONJ 
is limited, this review suggests that no useful markers 
are currently available to evaluate this risk. However, 
this review indicates that the paradigm shift from bone 
turnover biomarkers to angiogenesis and endocrine 
markers could shed light on this search. 
There is a need for the execution of new prospective 
studies that are capable of collecting representative 
samples of this infrequent pathology. International co-
operation for the creation of new multicentre studies is 
likely the best option. 
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